Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
February 06, 2025 06:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025 08:00 ET
|
Compass Therapeutics
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
January 28, 2025 07:05 ET
|
Clearside Biomedical, Inc.
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration...
ConeCraft Announces Partnership with T&C Stainless
January 27, 2025 13:58 ET
|
Cotton Creek Capital Management II, LLC
FORT WORTH, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ConeCraft, LLC (“ConeCraft”), a premier designer, engineer, and fabricator of custom processing equipment for the biopharmaceutical industry, is...
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
January 22, 2025 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of...
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
January 22, 2025 08:30 ET
|
Biodexa Pharmaceuticals PLC
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
January 22, 2025 07:05 ET
|
Clearside Biomedical, Inc.
- ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion of Clearside’s Suprachoroidal Space Injection Platform Featuring...
Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition
January 21, 2025 12:00 ET
|
Argentum 47, Inc.
Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:05 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Chromatographic Separation Resin Market is Predicted to Reach US$ 3.35 Billion, Expanding at a CAGR of 8.5% by 2034 | Fact.MR Report
January 06, 2025 07:30 ET
|
FACT.MR
Rockville, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global chromatographic separation resin market is estimated at US$...